Cardioverter defibrillators in primary prevention of sudden cardiac death: A cost or an investment?

Value in Health

Volumn 10, Issue 1, 2007, Pages 1-2

  Boriani, Giuseppe ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE;

CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; EDITORIAL; HEART DEATH; HEART DISEASE; HEART FAILURE; HUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; SUDDEN DEATH; TACHYCARDIA;

EID: 33846541478     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2006.00138.x     Document Type: Editorial

References (11)

1. Boriani G, Biffi M, Martignani C, et al. Cardioverter-defibrillators after MADIT-II: the balance between weight of evidence and treatment costs. Eur J Heart Fail 2003;5:419-25.
2. Al-Khatib SM, Sanders GD, Mark DB, et al. Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. Am Heart J 2005;149:1020-34.
3. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2005;46:e1-82.
4. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverterdefibrillators. N Engl J Med 2005;353:1471-80.
5. Bryant J, Brodin H, Loveman E, et al. The clinical and cost-effectiveness of implantable cardioverter defibrillators: a systematic review. Health Technol Assess 2005;9:1-150.
6. Caro JJ, Ward A, Deniz HB, et al. Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator (ICD) vs. amiodarone. Value Health 2007;10:(in press).
7. Hansjurgens B. Economic valuation through costbenefit analysis-possibilities and limitations. Toxicology 2004;205:241-52.
8. Donaldson C. The (near) equivalence of cost-effectiveness and cost-benefit analyses. Fact or fallacy? Pharmacoeconomics 1998;13:389-96.
9. Johri M, Damschroder LJ, Zikmund-Fisher BJ, Ubel PA. The importance of age in allocating health care resources: does intervention-type matter? Health Econ 2005;14:669-78.
10. Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. Eur J Heart Fail 2001;3:283-91.
11. Krahn AD, Connolly SJ, Roberts RS, et al. Diminishing proportional risk of sudden death with advancing age: implications for prevention of sudden death. Am Heart J 2004;147:837-40.